Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Drug Profile

Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Alternative Names: AAV Frataxin; AAV-delivered gene therapies for CNS disorders - Voyager Therapeutics; AAVrh.10-vectored PHF1; Amyotrophic lateral sclerosis gene therapy - Voyager Therapeutics; Anti-Tau Antibody; Friedreich’s ataxia gene therapy - Voyager Therapeutics; Huntington's disease gene therapy - Voyager Therapeutics; VY FXN01; VY HTT01; VY SMN101; VY SOD101; VY-NAV01; VY-TAU01

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Voyager Therapeutics
  • Class Analgesics; Antidementias; Gene therapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Gene transference; Nav1.7-voltage-gated-sodium-channel-inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Friedreich's ataxia; Huntington's disease; Pain; Spinal muscular atrophy

Most Recent Events

  • 16 Nov 2017 Pharmacodynamics data from a preclinical trial in Friedreich’s ataxia released by Voyager Therapeutics
  • 02 Nov 2017 Voyager Therapeutics announces intention to submit IND for VY FXN01 for Friedreich’s ataxia in 2019
  • 02 Nov 2017 Voyager Therapeutics announces intention to submit IND for VY HTT01 in Huntington’s disease and for VY SOD101 in Amyotrophic lateral sclerosis in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top